E7389
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout E7389
E7389 is a phase 1 stage product being developed by Eisai for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00326950. Target conditions include Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432886 | Phase 1 | Completed |
| NCT00413192 | Phase 2 | Completed |
| NCT00326950 | Phase 1 | Completed |
| NCT00278993 | Phase 2 | Completed |
| NCT00246090 | Phase 2 | Completed |
| NCT00097721 | Phase 2 | Completed |
| NCT00069264 | Phase 1 | Completed |
| NCT00069277 | Phase 1 | Completed |
Competing Products
20 competing products in Cancer